Neogenomics Lab Services

The Department of Veterans Affairs has awarded a sole-source, Indefinite Delivery/Indefinite Quantity (IDIQ) contract to NeoGenomics Laboratories, Inc. for specialized oncology and molecular testing services under solicitation number 36C26126D0032, with an award date of April 24, 2026. The contract, valued at an estimated $3.5 million to $5 million over five ordering periods from April 26, 2026, to April 25, 2031, provides critical diagnostic services including NeoTYPE cancer profiles, FISH assays, immunohistochemistry, molecular diagnostics, cytogenetics, and liquid biopsy testing. The award is justified under 41 USC §3304(a)(1) due to the proprietary nature of NeoGenomics’ NeoTYPE testing platform, which is uniquely validated and integrated into VA clinical workflows, with no other vendor able to replicate the same level of clinical accuracy, reporting consistency, or system compatibility. The contract includes an option to extend performance by up to six months under FAR clause 52.217-8, and all services are delivered under a firm fixed-price structure with no line-item pricing detailed, only aggregate annual and ceiling values. Specimens are collected by the VA Central California Healthcare System in Fresno, California, and transported to NeoGenomics’ primary laboratory in Fort Myers, Florida, where testing, analysis, and integrated diagnostic reporting are performed. Acceptance of test results occurs at the VA facility in Fresno, with the Government responsible for verifying clinical validity, timeliness, and adherence to validated protocols. Packaging, preservation, and labeling of specimens are acknowledged as part of the service but without detailed technical or regulatory standards specified. The contract does not include formal evaluation factors, weights, or competitive scoring due to its non-competitive nature, and no representations or certifications from the offeror are provided in the documentation. The contracting office is located in Mather, California, with Cynthia Diezel serving as the primary point of contact. The NAICS code 541380 applies, and while CLIA and CAP compliance is implied through clinical context, these are not formally cited. No COR/COTR appointments are named, and payment or accounting data such as TAS or AAC lines are not listed. The procurement process was conducted electronically via SAM.gov following a brief Notice of Intent period in February 2026, and the contract’s exclusivity is